BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Valle JW, Kelley RK, Nervi B, Oh DY, Zhu AX. Biliary tract cancer.Lancet. 2021;397:428-444. [PMID: 33516341 DOI: 10.1016/S0140-6736(21)00153-7] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 23.0] [Reference Citation Analysis]
Number Citing Articles
1 Cheng H, Zhou D, Wang S, Ding J, Ma F. Orphan drugs in different countries and development of new drugs to treat biliary tract cancer. Intractable Rare Dis Res 2021;10:146-7. [PMID: 33996363 DOI: 10.5582/irdr.2021.01038] [Reference Citation Analysis]
2 Chen CT, Goyal L. Paving a pathway for drug development in HER2-positive biliary tract cancer. Lancet Oncol 2021;22:1204-6. [PMID: 34478661 DOI: 10.1016/S1470-2045(21)00465-4] [Reference Citation Analysis]
3 Jiao CY, Zhang H, Ji GW, Xu Q, Lu M, Zhang B, Yang Y, Wang XH, Li XC. CT-based clinico-radiological nomograms for prognosis prediction in patients with intrahepatic mass-forming cholangiocarcinoma: a multi-institutional study. Eur Radiol 2022. [PMID: 35708837 DOI: 10.1007/s00330-022-08914-0] [Reference Citation Analysis]
4 Jackson SS, Pfeiffer RM, Gabbi C, Anderson L, Gadalla SM, Koshiol J. Menopausal hormone therapy and risk of biliary tract cancers. Hepatology 2022;75:309-21. [PMID: 34766362 DOI: 10.1002/hep.32198] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
5 De B, Tran Cao HS, Vauthey JN, Manzar GS, Corrigan KL, Raghav KPS, Lee SS, Tzeng CD, Minsky BD, Smith GL, Holliday EB, Taniguchi CM, Koong AC, Das P, Javle M, Ludmir EB, Koay EJ. Ablative liver radiotherapy for unresected intrahepatic cholangiocarcinoma: Patterns of care and survival in the United States. Cancer 2022. [PMID: 35417569 DOI: 10.1002/cncr.34223] [Reference Citation Analysis]
6 Wu Y, Hayat K, Hu Y, Yang J. Long Non-Coding RNAs as Molecular Biomarkers in Cholangiocarcinoma. Front Cell Dev Biol 2022;10:890605. [DOI: 10.3389/fcell.2022.890605] [Reference Citation Analysis]
7 Tang TY, Huang X, Zhang G, Lu MH, Liang TB. mRNA vaccine development for cholangiocarcinoma: a precise pipeline. Mil Med Res 2022;9:40. [PMID: 35821067 DOI: 10.1186/s40779-022-00399-8] [Reference Citation Analysis]
8 Zhang Z, Zhang W, Wang H, Hu B, Wang Z, Lu S. Successful Treatment of Advanced Intrahepatic Cholangiocarcinoma With a High Tumor Mutational Burden and PD-L1 Expression by PD-1 Blockade Combined With Tyrosine Kinase Inhibitors: A Case Report. Front Immunol 2021;12:744571. [PMID: 34603331 DOI: 10.3389/fimmu.2021.744571] [Reference Citation Analysis]
9 De B, Abu-Gheida I, Patel A, Ng SSW, Zaid M, Thunshelle CP, Elganainy D, Corrigan KL, Rooney MK, Javle M, Raghav K, Lee SS, Vauthey JN, Tzeng CD, Tran Cao HS, Ludmir EB, Minsky BD, Smith GL, Holliday EB, Taniguchi CM, Koong AC, Das P, Koay EJ. Benchmarking Outcomes after Ablative Radiotherapy for Molecularly Characterized Intrahepatic Cholangiocarcinoma. J Pers Med 2021;11:1270. [PMID: 34945742 DOI: 10.3390/jpm11121270] [Reference Citation Analysis]
10 Ardito F, Coppola A, Rinninella E, Razionale F, Pulcini G, Carano D, Cintoni M, Mele MC, Barbaro B, Giuliante F. Preoperative Assessment of Skeletal Muscle Mass and Muscle Quality Using Computed Tomography: Incidence of Sarcopenia in Patients with Intrahepatic Cholangiocarcinoma Selected for Liver Resection. J Clin Med 2022;11:1530. [PMID: 35329856 DOI: 10.3390/jcm11061530] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Suzuki S, Katagiri R, Yamaji T, Sawada N, Imatoh T, Ihira H, Inoue M, Tsugane S, Iwasaki M; Japan Public Health Center-based Prospective Study Group. Association between C-reactive protein and risk of overall and 18 site-specific cancers in a Japanese case-cohort. Br J Cancer 2022. [PMID: 35140343 DOI: 10.1038/s41416-022-01715-8] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Koessler T, Alsina M, Arnold D, Ben-Aharon I, Collienne M, Lutz MP, Neuzillet C, Obermannova R, Peeters M, Sclafani F, Smyth E, Valle JW, Wagner AD, Wyrwicz L, Fontana E, Moehler M. ESMO Congress 2021: highlights from the EORTC gastrointestinal tract cancer group's perspective. ESMO Open 2022;7:100392. [PMID: 35180656 DOI: 10.1016/j.esmoop.2022.100392] [Reference Citation Analysis]
13 Goktas Aydin S, Cakan Demirel B, Bilici A, Topcu A, Aykan MB, Kahraman S, Akbıyık I, Atci MM, Olmez OF, Yaren A, Geredeli C, Seker M, Urun Y, Karadurmus N, Aydin A. Real-life analysis of treatment approaches and the role of inflammatory markers on survival in patients with advanced biliary tract cancer. Curr Med Res Opin 2022;:1-24. [PMID: 35916475 DOI: 10.1080/03007995.2022.2108619] [Reference Citation Analysis]
14 Herold Z, Szasz AM, Dank M. Evidence based tools to improve efficiency of currently administered oncotherapies for tumors of the hepatopancreatobiliary system. World J Gastrointest Oncol 2021;13:1109-20. [PMID: 34616516 DOI: 10.4251/wjgo.v13.i9.1109] [Reference Citation Analysis]
15 Hu X, Zhang J, Bu J, Yang K, Xu S, Pan M, Xiang D, Chen W. MiR-4733-5p promotes gallbladder carcinoma progression via directly targeting kruppel like factor 7. Bioengineered 2022;13:10691-706. [PMID: 35443866 DOI: 10.1080/21655979.2022.2065951] [Reference Citation Analysis]
16 Zhang R, Puzzoni M, Mariani S, Zheng Y, Liscia N, Guo Y, Donisi C, Liu Y, Impera V, Fang W, Scartozzi M. Emerging treatment evolutions and integrated molecular characteristics of biliary tract cancers. Cancer Sci 2021. [PMID: 34534382 DOI: 10.1111/cas.15139] [Reference Citation Analysis]
17 Wang L, Li X, Cheng Y, Yang J, Liu S, Ma T, Luo L, Hu Y, Cai Y, Yan D. Case Report: Addition of PD-1 Antibody Camrelizumab Overcame Resistance to Trastuzumab Plus Chemotherapy in a HER2-Positive, Metastatic Gallbladder Cancer Patient. Front Immunol 2021;12:784861. [PMID: 35069555 DOI: 10.3389/fimmu.2021.784861] [Reference Citation Analysis]
18 Li H, Qu L, Zhang H, Liu J, Zhang X. A comprehensive transcriptomic landscape of cholangiocarcinoma based on bioinformatics analysis from large cohort of patients. Sci Rep 2021;11:13713. [PMID: 34211100 DOI: 10.1038/s41598-021-93250-4] [Reference Citation Analysis]
19 Chen X, Rong D, Zhang L, Ni C, Han G, Lu Y, Chen X, Gao Y, Wang X. Evaluation of nodal status in intrahepatic cholangiocarcinoma: a population-based study. Ann Transl Med 2021;9:1359. [PMID: 34733911 DOI: 10.21037/atm-21-2785] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Li H, Lan T, Liu H, Liu C, Dai J, Xu L, Cai Y, Hou G, Xie K, Liao M, Li J, Huang J, Yuan K, Wang G, Zeng Y, Wu H. IL-6-induced cGGNBP2 encodes a protein to promote cell growth and metastasis in intrahepatic cholangiocarcinoma. Hepatology 2022;75:1402-19. [PMID: 34758510 DOI: 10.1002/hep.32232] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
21 Wang Z, Zhang Y, Chen Y, Liu S, Li C, Li X. Identification of a Ferroptosis-related Gene Signature for Predicting the Prognosis of Cholangiocarcinoma. Expert Rev Gastroenterol Hepatol 2022. [PMID: 35026122 DOI: 10.1080/17474124.2022.2029700] [Reference Citation Analysis]
22 Liu Z, Hu C, Zheng L, Liu J, Li K, Li X, Wang Y, Mu W, Chen T, Shi A, Qiu B, Zhang X, Zhang Z, Xu Y. BMI1 promotes cholangiocarcinoma progression and correlates with antitumor immunity in an exosome-dependent manner. Cell Mol Life Sci 2022;79:469. [PMID: 35932322 DOI: 10.1007/s00018-022-04500-1] [Reference Citation Analysis]
23 Ioffe D, Phull P, Dotan E. Optimal Management of Patients with Advanced or Metastatic Cholangiocarcinoma: An Evidence-Based Review. Cancer Manag Res 2021;13:8085-98. [PMID: 34737637 DOI: 10.2147/CMAR.S276104] [Reference Citation Analysis]
24 Deng M, Li SH, Fu X, Yan XP, Chen J, Qiu YD, Guo RP. Relationship between PD-L1 expression, CD8+ T-cell infiltration and prognosis in intrahepatic cholangiocarcinoma patients. Cancer Cell Int 2021;21:371. [PMID: 34253205 DOI: 10.1186/s12935-021-02081-w] [Reference Citation Analysis]
25 Fabritius MP, Ben Khaled N, Kunz WG, Ricke J, Seidensticker M. Image-Guided Local Treatment for Unresectable Intrahepatic Cholangiocarcinoma-Role of Interventional Radiology. J Clin Med 2021;10:5574. [PMID: 34884275 DOI: 10.3390/jcm10235574] [Reference Citation Analysis]
26 Liu C, Li Y, Zhang L, Zhang P, Yu N, Liu X, Lu H, Du H, Hou S, Kang Z. MiRNA-196-5p Promotes Proliferation and Migration in Cholangiocarcinoma via HAND1/Wnt/β-Catenin Signaling Pathway. Journal of Oncology 2022;2022:1-10. [DOI: 10.1155/2022/4599676] [Reference Citation Analysis]
27 Saffioti F, Mavroeidis VK. Review of incidence and outcomes of treatment of cholangiocarcinoma in patients with primary sclerosing cholangitis. World J Gastrointest Oncol 2021; 13(10): 1336-1366 [PMID: 34721770 DOI: 10.4251/wjgo.v13.i10.1336] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Posch F, Prinz F, Balihodzic A, Mayr C, Kiesslich T, Klec C, Jonas K, Barth DA, Riedl JM, Gerger A, Pichler M. MiR-200c-3p Modulates Cisplatin Resistance in Biliary Tract Cancer by ZEB1-Independent Mechanisms. Cancers (Basel) 2021;13:3996. [PMID: 34439151 DOI: 10.3390/cancers13163996] [Reference Citation Analysis]
29 Hucke F, Pinter M, Hucke M, Bota S, Bolf D, Hackl M, Peck-radosavljevic M. Changing Epidemiological Trends of Hepatobiliary Carcinomas in Austria 2010–2018. Cancers 2022;14:3093. [DOI: 10.3390/cancers14133093] [Reference Citation Analysis]
30 Zhuravleva E, O'Rourke CJ, Andersen JB. Mutational signatures and processes in hepatobiliary cancers. Nat Rev Gastroenterol Hepatol 2022;19:367-82. [PMID: 35273358 DOI: 10.1038/s41575-022-00587-w] [Reference Citation Analysis]
31 Elshami M, Ahmed FA, Kakish H, Hue JJ, Hoehn RS, Rothermel LD, Bajor D, Mohamed A, Selfridge J, Ammori JB, Hardacre JM, Winter JM, Ocuin LM. Average treatment effect of facility hepatopancreatobiliary cancer volume on survival of non-resected pancreatic adenocarcinoma. HPB 2022. [DOI: 10.1016/j.hpb.2022.07.007] [Reference Citation Analysis]
32 Ciardiello D, Maiorano BA, Parente P, Rodriquenz MG, Latiano TP, Chiarazzo C, Pazienza V, Guerrera LP, Amoruso B, Normanno N, Martini G, Ciardiello F, Martinelli E, Maiello E. Immunotherapy for Biliary Tract Cancer in the Era of Precision Medicine: Current Knowledge and Future Perspectives. Int J Mol Sci 2022;23:820. [PMID: 35055006 DOI: 10.3390/ijms23020820] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
33 Huang X, Niu X, You Z, Long Y, Luo F, Ye H. Comparison of Four Lymph Node Stage Methods for Predicting the Prognosis of Distal Cholangiocarcinoma Patients After Surgery. Front Oncol 2021;11:779761. [PMID: 34926292 DOI: 10.3389/fonc.2021.779761] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Wheatley RC, Kilgour E, Jacobs T, Lamarca A, Hubner RA, Valle JW, McNamara MG. Potential influence of the microbiome environment in patients with biliary tract cancer and implications for therapy. Br J Cancer 2021. [PMID: 34663949 DOI: 10.1038/s41416-021-01583-8] [Reference Citation Analysis]
35 Kang S, El-Rayes BF, Akce M. Evolving Role of Immunotherapy in Advanced Biliary Tract Cancers. Cancers (Basel) 2022;14:1748. [PMID: 35406520 DOI: 10.3390/cancers14071748] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Hemminki K, Sundquist K, Sundquist J, Försti A, Liska V, Hemminki A, Li X. Familial Risks for Liver, Gallbladder and Bile Duct Cancers and for Their Risk Factors in Sweden, a Low-Incidence Country. Cancers (Basel) 2022;14:1938. [PMID: 35454845 DOI: 10.3390/cancers14081938] [Reference Citation Analysis]
37 Khan TM, Verbus EA, Hong H, Ethun CG, Maithel SK, Hernandez JM. Perioperative Versus Adjuvant Chemotherapy in the Management of Incidentally Found Gallbladder Cancer (OPT-IN). Ann Surg Oncol 2021. [PMID: 34132951 DOI: 10.1245/s10434-021-10277-7] [Reference Citation Analysis]
38 Wang S, Tong H, Su T, Zhou D, Shi W, Tang Z, Quan Z. CircTP63 promotes cell proliferation and invasion by regulating EZH2 via sponging miR-217 in gallbladder cancer. Cancer Cell Int 2021;21:608. [PMID: 34789260 DOI: 10.1186/s12935-021-02316-w] [Reference Citation Analysis]
39 Kai Y, Ikezawa K, Takada R, Daiku K, Maeda S, Abe Y, Yamai T, Fukutake N, Nakabori T, Uehara H, Nagata S, Wada H, Ohkawa K. Success rate of microsatellite instability examination and complete response with pembrolizumab in biliary tract cancer. JGH Open 2021;5:712-6. [PMID: 34124390 DOI: 10.1002/jgh3.12576] [Reference Citation Analysis]
40 Joechle K, Guenzle J, Hellerbrand C, Strnad P, Cramer T, Neumann UP, Lang SA. Role of mammalian target of rapamycin complex 2 in primary and secondary liver cancer. World J Gastrointest Oncol 2021; 13(11): 1632-1647 [PMID: 34853640 DOI: 10.4251/wjgo.v13.i11.1632] [Reference Citation Analysis]
41 Mayr C, Kiesslich T, Modest DP, Stintzing S, Ocker M, Neureiter D. Chemoresistance and resistance to targeted therapies in biliary tract cancer: What have we learned? Expert Opin Investig Drugs 2022. [PMID: 35098846 DOI: 10.1080/13543784.2022.2034785] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Makiuchi T, Sobue T. Descriptive epidemiology of biliary tract cancer incidence and geographic variation in Japan. Eur J Cancer Prev 2022. [PMID: 35485392 DOI: 10.1097/CEJ.0000000000000758] [Reference Citation Analysis]
43 Mao J, Wang D, Long J, Yang X, Lin J, Song Y, Xie F, Xun Z, Wang Y, Wang Y, Li Y, Sun H, Xue J, Song Y, Zuo B, Zhang J, Bian J, Zhang T, Yang X, Zhang L, Sang X, Zhao H. Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers. J Immunother Cancer 2021;9:e003334. [PMID: 34873013 DOI: 10.1136/jitc-2021-003334] [Reference Citation Analysis]
44 Wang SY, Jiang N, Zeng JP, Yu SQ, Xiao Y, Jin S. Characteristic of Perineural Invasion in Hilar Cholangiocarcinoma Based on Whole-Mount Histologic Large Sections of Liver. Front Oncol 2022;12:855615. [PMID: 35350570 DOI: 10.3389/fonc.2022.855615] [Reference Citation Analysis]
45 Gray S, Lamarca A, Edeline J, Klümpen H, Hubner RA, Mcnamara MG, Valle JW. Targeted Therapies for Perihilar Cholangiocarcinoma. Cancers 2022;14:1789. [DOI: 10.3390/cancers14071789] [Reference Citation Analysis]
46 Du J, Lan T, Liao H, Feng X, Chen X, Liao W, Hou G, Xu L, Feng Q, Xie K, Liao M, Chen X, Huang J, Yuan K, Zeng Y. CircNFIB inhibits tumor growth and metastasis through suppressing MEK1/ERK signaling in intrahepatic cholangiocarcinoma. Mol Cancer 2022;21:18. [PMID: 35039066 DOI: 10.1186/s12943-021-01482-9] [Reference Citation Analysis]
47 Cao J, Shao H, Hu J, Jin R, Feng A, Zhang B, Li S, Chen T, Jeungpanich S, Topatana W, Tian Y, Lu Z, Cai X, Chen M. Identification of invasion-metastasis associated MiRNAs in gallbladder cancer by bioinformatics and experimental validation. J Transl Med 2022;20:188. [PMID: 35484565 DOI: 10.1186/s12967-022-03394-8] [Reference Citation Analysis]
48 Marin JJG, Sanchon-Sanchez P, Cives-Losada C, Del Carmen S, González-Santiago JM, Monte MJ, Macias RIR. Novel Pharmacological Options in the Treatment of Cholangiocarcinoma: Mechanisms of Resistance. Cancers (Basel) 2021;13:2358. [PMID: 34068398 DOI: 10.3390/cancers13102358] [Reference Citation Analysis]
49 Chen Q, Lu J, Lu X, Yao X, Zhang X, Wang S, Guo J. The Prognostic Value of Sarcopenia and Myosteatosis in Biliary Tract Cancer After Palliative Treatment With Radiation-Emitting Metallic Stent. Front Surg 2022;9:852137. [DOI: 10.3389/fsurg.2022.852137] [Reference Citation Analysis]
50 Casadio M, Biancaniello F, Overi D, Venere R, Carpino G, Gaudio E, Alvaro D, Cardinale V. Molecular Landscape and Therapeutic Strategies in Cholangiocarcinoma: An Integrated Translational Approach towards Precision Medicine. Int J Mol Sci 2021;22:5613. [PMID: 34070643 DOI: 10.3390/ijms22115613] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
51 Ren Y, Wang X, Ji T, Cai X. MicroRNA-146b-5p suppresses cholangiocarcinoma cells by targeting TRAF6 and modulating p53 translocation. Acta Histochem 2021;123:151793. [PMID: 34610483 DOI: 10.1016/j.acthis.2021.151793] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
52 Uson Junior PLS, Borad MJ. Precision approaches for cholangiocarcinoma: Progress in clinical trials and beyond. Expert Opin Investig Drugs 2021. [PMID: 34904492 DOI: 10.1080/13543784.2022.2017882] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
53 Hunter LA, Soares HP. Quality of Life and Symptom Management in Advanced Biliary Tract Cancers. Cancers (Basel) 2021;13:5074. [PMID: 34680223 DOI: 10.3390/cancers13205074] [Reference Citation Analysis]
54 Wang Y, Chen T, Li K, Mu W, Liu Z, Shi A, Liu J, Zhao W, Lian S, Huang S, Pan C, Zhang Z. Recent Advances in the Mechanism Research and Clinical Treatment of Anti-Angiogenesis in Biliary Tract Cancer. Front Oncol 2021;11:777617. [PMID: 34778094 DOI: 10.3389/fonc.2021.777617] [Reference Citation Analysis]
55 Conci S, Campagnaro T, Danese E, Lombardo E, Isa G, Vitali A, Marchitelli I, Bagante F, Pedrazzani C, De Bellis M, Ciangherotti A, Guglielmi A, Lippi G, Ruzzenente A. Role of Inflammatory and Immune-Nutritional Prognostic Markers in Patients Undergoing Surgical Resection for Biliary Tract Cancers. Cancers (Basel) 2021;13:3594. [PMID: 34298807 DOI: 10.3390/cancers13143594] [Reference Citation Analysis]
56 Thol F, Gairing SJ, Czauderna C, Thomaidis T, Gamstätter T, Huber Y, Vollmar J, Lorenz J, Michel M, Bartsch F, Müller L, Kloeckner R, Galle PR, Wörns M, Marquardt JU, Moehler M, Weinmann A, Foerster F. Outcomes in patients receiving palliative chemotherapy for advanced biliary tract cancer. JHEP Reports 2022;4:100417. [DOI: 10.1016/j.jhepr.2021.100417] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
57 Kim-Fuchs C, Candinas D, Lachenmayer A. The Role of Conventional and Stereotactic Microwave Ablation for Intrahepatic Cholangiocarcinoma. J Clin Med 2021;10:2963. [PMID: 34279447 DOI: 10.3390/jcm10132963] [Reference Citation Analysis]
58 Liu J, Ren G, Li K, Liu Z, Wang Y, Chen T, Mu W, Yang X, Li X, Shi A, Zhao W, Xu B, Chang J, Guo S, Pan C, Zhou T, Zhang Z, Xu Y. The Smad4-MYO18A-PP1A complex regulates β-catenin phosphorylation and pemigatinib resistance by inhibiting PAK1 in cholangiocarcinoma. Cell Death Differ 2021. [PMID: 34799729 DOI: 10.1038/s41418-021-00897-7] [Reference Citation Analysis]
59 Liu Z, Liu J, Chen T, Wang Y, Shi A, Li K, Li X, Qiu B, Zheng L, Zhao L, Shu L, Lian S, Huang S, Zhang Z, Xu Y. Wnt-TCF7-SOX9 axis promotes cholangiocarcinoma proliferation and pemigatinib resistance in a FGF7-FGFR2 autocrine pathway. Oncogene. [DOI: 10.1038/s41388-022-02313-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
60 Hack SP, Verret W, Mulla S, Liu B, Wang Y, Macarulla T, Ren Z, El-Khoueiry AB, Zhu AX. IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer. Ther Adv Med Oncol 2021;13:17588359211036544. [PMID: 34377158 DOI: 10.1177/17588359211036544] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
61 Rodrigues PM, Vogel A, Arrese M, Balderramo DC, Valle JW, Banales JM. Next-Generation Biomarkers for Cholangiocarcinoma. Cancers (Basel) 2021;13:3222. [PMID: 34203269 DOI: 10.3390/cancers13133222] [Reference Citation Analysis]
62 Neuzillet C. First-line chemotherapy plus immunotherapy in biliary tract cancer. The Lancet Gastroenterology & Hepatology 2022;7:496-7. [DOI: 10.1016/s2468-1253(22)00052-8] [Reference Citation Analysis]
63 Scott AJ, Sharman R, Shroff RT. Precision Medicine in Biliary Tract Cancer. J Clin Oncol 2022;:JCO2102576. [PMID: 35839428 DOI: 10.1200/JCO.21.02576] [Reference Citation Analysis]
64 Pérez-moreno P, Riquelme I, García P, Brebi P, Roa JC. Environmental and Lifestyle Risk Factors in the Carcinogenesis of Gallbladder Cancer. JPM 2022;12:234. [DOI: 10.3390/jpm12020234] [Reference Citation Analysis]
65 Wang J, Zhuge J, Feng D, Zhang B, Xu J, Zhao D, Fei Z, Huang X, Shi W. Mendelian randomization study of circulating lipids and biliary tract cancer among East Asians. BMC Cancer 2022;22:273. [PMID: 35291981 DOI: 10.1186/s12885-022-09382-x] [Reference Citation Analysis]
66 Weng X, Song X, Shao R, Liu F, Liu Y. Aging and biliary tract cancers: Epidemiology, molecular biology, and clinical practice. Aging and Cancer 2022;3:95-104. [DOI: 10.1002/aac2.12054] [Reference Citation Analysis]
67 Sasaki T, Takeda T, Okamoto T, Ozaka M, Sasahira N. Chemotherapy for Biliary Tract Cancer in 2021. J Clin Med 2021;10:3108. [PMID: 34300274 DOI: 10.3390/jcm10143108] [Reference Citation Analysis]
68 Oh D, Ruth He A, Qin S, Chen L, Okusaka T, Vogel A, Kim JW, Suksombooncharoen T, Ah Lee M, Kitano M, Burris H, Bouattour M, Tanasanvimon S, Mcnamara MG, Zaucha R, Avallone A, Tan B, Cundom J, Lee C, Takahashi H, Ikeda M, Chen J, Wang J, Makowsky M, Rokutanda N, He P, Kurland JF, Cohen G, Valle JW. Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer. NEJM Evidence. [DOI: 10.1056/evidoa2200015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
69 Woods E, Le D, Jakka BK, Manne A. Changing Landscape of Systemic Therapy in Biliary Tract Cancer. Cancers (Basel) 2022;14:2137. [PMID: 35565266 DOI: 10.3390/cancers14092137] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
70 Ohba A, Morizane C, Ueno M, Kobayashi S, Kawamoto Y, Komatsu Y, Ikeda M, Sasaki M, Okano N, Furuse J, Hiraoka N, Yoshida H, Kuchiba A, Sadachi R, Nakamura K, Matsui N, Nakamura Y, Okamoto W, Yoshino T, Okusaka T. Multicenter phase II trial of trastuzumab deruxtecan for HER2-positive unresectable or recurrent biliary tract cancer: HERB trial. Future Oncol 2022. [PMID: 35510484 DOI: 10.2217/fon-2022-0214] [Reference Citation Analysis]
71 Liu T, Li Q, Zhang W, Zhu Q. Long-Term Response to Gemcitabine, Cisplatin, and Nab-Paclitaxel Followed by Maintenance Therapy for Advanced Gallbladder Cancer: A Case Report and Literature Review. Front Oncol 2021;11:733955. [PMID: 34676166 DOI: 10.3389/fonc.2021.733955] [Reference Citation Analysis]
72 Prete MG, Cammarota A, D'alessio A, Zanuso V, Rimassa L. Current options and future directions of systemic therapy for advanced biliary tract cancer. Exploration of Targeted Anti-tumor Therapy 2021;2. [DOI: 10.37349/etat.2021.00054] [Reference Citation Analysis]
73 Yang X, Sun Y, Li D, Xu G, Huang X. Efficacy and Safety of Drug-Eluting Beads Transarterial Chemoembolization Combining Immune Checkpoint Inhibitors in Unresectable Intrahepatic Cholangiocarcinoma: A Propensity Score Matching Analysis. Front Immunol 2022;13:940009. [DOI: 10.3389/fimmu.2022.940009] [Reference Citation Analysis]
74 Sun W, Wan W, Gao Z, Suo T, Shen S, Liu H. Publication Trends of Research on Gallbladder Cancer During 2001–2021: A 20-Year Bibliometric Analysis. Front Oncol 2022;12:932797. [DOI: 10.3389/fonc.2022.932797] [Reference Citation Analysis]
75 Deng M, Li S, Wang Q, Zhao R, Zou J, Lin W, Mei J, Wei W, Guo R. Real-world outcomes of patients with advanced intrahepatic cholangiocarcinoma treated with programmed cell death protein-1-targeted immunotherapy. Ann Med 2022;54:803-11. [PMID: 35272564 DOI: 10.1080/07853890.2022.2048416] [Reference Citation Analysis]
76 Manne A, Woods E, Tsung A, Mittra A. Biliary Tract Cancers: Treatment Updates and Future Directions in the Era of Precision Medicine and Immuno-Oncology. Front Oncol 2021;11:768009. [PMID: 34868996 DOI: 10.3389/fonc.2021.768009] [Reference Citation Analysis]
77 Park HM, Won YJ, Kang MJ, Park SJ, Kim SW, Jung KW, Han SS. Trend Analysis and Prediction of Hepatobiliary Pancreatic Cancer Incidence and Mortality in Korea. J Korean Med Sci 2022;37:e216. [PMID: 35851861 DOI: 10.3346/jkms.2022.37.e216] [Reference Citation Analysis]
78 Raggi C, Taddei ML, Rae C, Braconi C, Marra F. Metabolic Reprogramming in Cholangiocarcinoma. J Hepatol 2022:S0168-8278(22)00314-2. [PMID: 35594992 DOI: 10.1016/j.jhep.2022.04.038] [Reference Citation Analysis]
79 Chen R, Zhang Y, Lin K, Huang D, You M, Lai Y, Wang J, Hu Y, Li N. Cost-Effectiveness Analysis of Capecitabine Plus Oxaliplatin Versus Gemcitabine Plus Oxaliplatin as First-Line Therapy for Advanced Biliary Tract Cancers. Front Pharmacol 2022;13:871262. [DOI: 10.3389/fphar.2022.871262] [Reference Citation Analysis]
80 Wang Y, Yang X, Wang D, Yang X, Wang Y, Long J, Zhou J, Lu Z, Mao Y, Sang X, Guan M, Zhao H. Lenvatinib Beyond First-Line Therapy in Patients With Advanced Biliary Tract Carcinoma. Front Oncol 2022;12:785535. [DOI: 10.3389/fonc.2022.785535] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
81 Li H, Liu R, Qiu H, Huang Y, Liu W, Li J, Wu H, Wang G, Li D. Tumor Burden Score Stratifies Prognosis of Patients With Intrahepatic Cholangiocarcinoma After Hepatic Resection: A Retrospective, Multi-Institutional Study. Front Oncol 2022;12:829407. [PMID: 35330712 DOI: 10.3389/fonc.2022.829407] [Reference Citation Analysis]
82 Arechederra M, Rullán M, Amat I, Oyon D, Zabalza L, Elizalde M, Latasa MU, Mercado MR, Ruiz-Clavijo D, Saldaña C, Fernández-Urién I, Carrascosa J, Jusué V, Guerrero-Setas D, Zazpe C, González-Borja I, Sangro B, Herranz JM, Purroy A, Gil I, Nelson LJ, Vila JJ, Krawczyk M, Zieniewicz K, Patkowski W, Milkiewicz P, Cubero FJ, Alkorta-Aranburu G, G Fernandez-Barrena M, Urman JM, Berasain C, Avila MA. Next-generation sequencing of bile cell-free DNA for the early detection of patients with malignant biliary strictures. Gut 2022;71:1141-51. [PMID: 34285068 DOI: 10.1136/gutjnl-2021-325178] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
83 Macias RIR, Cardinale V, Kendall TJ, Avila MA, Guido M, Coulouarn C, Braconi C, Frampton AE, Bridgewater J, Overi D, Pereira SP, Rengo M, Kather JN, Lamarca A, Pedica F, Forner A, Valle JW, Gaudio E, Alvaro D, Banales JM, Carpino G. Clinical relevance of biomarkers in cholangiocarcinoma: critical revision and future directions. Gut 2022:gutjnl-2022-327099. [PMID: 35580963 DOI: 10.1136/gutjnl-2022-327099] [Reference Citation Analysis]
84 Liu X, Jiang Y, Sun X, Zhao J, Zhang L, Jing X. Prognostic Significance of the Systemic Immune-Inflammation Index in Patients With Cholangiocarcinoma: A Meta-Analysis. Front Oncol 2022;12:938549. [DOI: 10.3389/fonc.2022.938549] [Reference Citation Analysis]
85 Kang MJ, Lim J, Han SS, Park HM, Kim SW, Lee WJ, Woo SM, Kim TH, Won YJ, Park SJ. Distinct prognosis of biliary tract cancer according to tumor location, stage, and treatment: a population-based study. Sci Rep 2022;12:10206. [PMID: 35715440 DOI: 10.1038/s41598-022-13605-3] [Reference Citation Analysis]
86 Cao J, Wang Y, Zhang B, Hu J, Topatana W, Li S, Juengpanich S, Lu Z, Cai X, Chen M. Comparison of Outcomes After Primary Laparoscopic Versus Open Approach for T1b/T2 Gallbladder Cancer. Front Oncol 2021;11:758319. [PMID: 34778076 DOI: 10.3389/fonc.2021.758319] [Reference Citation Analysis]
87 Jördens MS, Heinrichs L, Loosen SH, Wittig L, Keitel V, Schöler D, Schulze-Hagen M, Loberg C, Antoch G, Knoefel WT, Luedde T, Fluegen G, Roderburg C. Sarcopenia Predicts Cancer Mortality in Male but Not in Female Patients Undergoing Surgery for Cholangiocellular Carcinoma. Cancers (Basel) 2021;13:5359. [PMID: 34771524 DOI: 10.3390/cancers13215359] [Reference Citation Analysis]
88 Lin ZQ, Ma C, Cao WZ, Ning Z, Tan G. Prognostic Significance of NLR, PLR, LMR and Tumor Infiltrating T Lymphocytes in Patients Undergoing Surgical Resection for Hilar Cholangiocarcinoma. Front Oncol 2022;12:908907. [PMID: 35719959 DOI: 10.3389/fonc.2022.908907] [Reference Citation Analysis]
89 Jördens MS, Wittig L, Heinrichs L, Keitel V, Schulze-Hagen M, Antoch G, Knoefel WT, Fluegen G, Luedde T, Loberg C, Roderburg C, Loosen SH. Sarcopenia and Myosteatosis as Prognostic Markers in Patients with Advanced Cholangiocarcinoma Undergoing Palliative Treatment. J Clin Med 2021;10:4340. [PMID: 34640358 DOI: 10.3390/jcm10194340] [Reference Citation Analysis]
90 Holster JJ, El Hassnaoui M, Franssen S, IJzermans JNM, de Jonge J, Mostert B, Polak WG, de Wilde RF, Homs MYV, Groot Koerkamp B. Hepatic Arterial Infusion Pump Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma: A Systematic Review and Meta-Analysis. Ann Surg Oncol 2022. [PMID: 35294656 DOI: 10.1245/s10434-022-11439-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
91 Li H, Liu R, Li J, Li J, Wu H, Wang G, Li Z, Li D. Prognostic significance of gamma-glutamyl transpeptidase to albumin ratio in patients with intrahepatic cholangiocarcinoma after hepatectomy. J Cell Mol Med 2022. [PMID: 35481993 DOI: 10.1111/jcmm.17321] [Reference Citation Analysis]
92 Chen T, Liu H, Liu Z, Li K, Qin R, Wang Y, Liu J, Li Z, Gao Q, Pan C, Yang F, Zhao W, Zhang Z, Xu Y. FGF19 and FGFR4 promotes the progression of gallbladder carcinoma in an autocrine pathway dependent on GPBAR1-cAMP-EGR1 axis. Oncogene 2021;40:4941-53. [PMID: 34163030 DOI: 10.1038/s41388-021-01850-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
93 Phelip JM, Desrame J, Edeline J, Barbier E, Terrebonne E, Michel P, Perrier H, Dahan L, Bourgeois V, Akouz FK, Soularue E, Ly VL, Molin Y, Lecomte T, Ghiringhelli F, Coriat R, Louafi S, Neuzillet C, Manfredi S, Malka D; PRODIGE 38 AMEBICA Investigators/Collaborators. Modified FOLFIRINOX Versus CISGEM Chemotherapy for Patients With Advanced Biliary Tract Cancer (PRODIGE 38 AMEBICA): A Randomized Phase II Study. J Clin Oncol 2021;:JCO2100679. [PMID: 34662180 DOI: 10.1200/JCO.21.00679] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
94 Roderburg C, Loosen SH, Bednarsch J, Alizai PH, Roeth AA, Schmitz SM, Vucur M, Luedde M, Paffenholz P, Tacke F, Trautwein C, Ulmer TF, Neumann UP, Luedde T. Levels of Circulating PD-L1 Are Decreased in Patients with Resectable Cholangiocarcinoma. Int J Mol Sci 2021;22:6569. [PMID: 34207359 DOI: 10.3390/ijms22126569] [Reference Citation Analysis]